Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Clinical Relevance of Alternatively Spliced Isoform AML1-ETO9a in Adult Patients with t(8;21)(q22;q22.1) Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG)

Blood (2017) 130 (Supplement 1): 2685.

https://doi.org/10.1182/blood.V130.Suppl_1.2685.2685

Published: 2017

Journal Articles

CDK4/6 Inhibitor Palbociclib for Treatment of KMT2A -Rearranged Acute Myeloid Leukemia: Interim Analysis of the AMLSG 23-14 Trial

Stefan Fröhling, MD, Mridul Agrawal, MD, Nikolaus Jahn, MD, Lars R. Fransecky, MD, Claudia D. Baldus, MD, Ralph Wäsch, MD, Michael Lübbert, MD, Gina Walter, PhD, Patrizia Jensen, Claudia Scholl, MD, Marianne Habdank, Konstanze Döhner, Hartmut Döhner, MD, Richard F. Schlenk, MD

Blood (2016) 128 (22): 1608.

https://doi.org/10.1182/blood.V128.22.1608.1608

Published: 2016

Journal Articles

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

Blood (2012) 119 (9): 2114–2121.

https://doi.org/10.1182/blood-2011-08-375758

Published: 2012

Includes: Supplemental data

Journal Articles

TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome,

Blood (2011) 118 (21): 3558.

https://doi.org/10.1182/blood.V118.21.3558.3558

Published: 2011

Journal Articles

ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG

Blood (2011) 118 (21): 412.

https://doi.org/10.1182/blood.V118.21.412.412

Published: 2011

Journal Articles

TET2 Mutations In Acute Myeloid Leukemia (AML): Results on 783 Patients Treated within the AML HD98A Study of the AML Study Group (AMLSG)

Verena I. Gaidzik, MD, Richard F. Schlenk, MD, Peter Paschka, MD, Claus-Henning Köhne, MD, Gerhard Held, MD, Marianne Habdank, Juliane Gohlke, Hans-Günther Mergenthaler, MD, Hans J. Salwender, MD, Lars Bullinger, MD, Hartmut Döhner, MD, Konstanze Döhner, MD

Blood (2010) 116 (21): 97.

https://doi.org/10.1182/blood.V116.21.97.97

Published: 2010

Journal Articles

Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG).

Jan Krönke, Richard Schlenk, Kai-Ole Jensen, Karina Eiwen, Marianne Habdank, Daniela Späth, Jürgen Krauter, Arnold Ganser, Prof./M.D., Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Hartmut Döhner, Konstanze Döhner

Blood (2009) 114 (22): 1586.

https://doi.org/10.1182/blood.V114.22.1586.1586

Published: 2009

Journal Articles

Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG)

Jan Krönke, Richard Schlenk, Kai-Ole Jensen, Karina Eiwen, Marianne Habdank, Daniela Späth, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Konstanze Döhner

Blood (2008) 112 (11): 699.

https://doi.org/10.1182/blood.V112.11.699.699

Published: 2008

Journal Articles

The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.

Richard F. Schlenk, MD, Konstanze Döhner, MD, Michael Kneba, MD, Francesco del Valle, MD, Frank Hartmann, MD, Heinz Kirchen, MD, Elisabeth Koller, MD, Katharina Götze, MD, Jörg Th. Fischer, MD, Marianne Habdank, Daniela Späth, Silja Groner, Andrea Corbacioglu, Axel Benner, MSC, Stefan Fröhling, Hartmut Döhner

Blood (2007) 110 (11): 297.

https://doi.org/10.1182/blood.V110.11.297.297

Published: 2007

Journal Articles

CEBPA Germline Mutation Screening in Cytogenetically Normal Acute Myeloid Leukemia with Somatically Acquired CEBPA Mutations.

Andrea Corbacioglu, PhD, Stefan Fröhling, MD, Corinna Mendla, Karina Eiwen, Marianne Habdank, Hartmut Döhner, MD, Richard F. Schlenk, MD, Konstanze Döhner, MD

Blood (2007) 110 (11): 363.

https://doi.org/10.1182/blood.V110.11.363.363

Published: 2007

Journal Articles

Clinical Impact of WT1 Mutations in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG).

Verena I. Gaidzik, MD, Marianne Habdank, Simone Moschny, Silja Groner, Daniela Spath, Jurgen Krauter, MD, Brigitte Schlegelberger, MD, Arnold Ganser, MD, Hartmut Dohner, MD, Richard F. Schlenk, Konstanze Dohner, MD

Blood (2007) 110 (11): 364.

https://doi.org/10.1182/blood.V110.11.364.364

Published: 2007

Journal Articles

Detection of RAS, KIT and FLT3 Gene Mutations in t(8;21)-Positive Acute Myeloid Leukemia (AML): Evaluation of the Clinical Relevance.

Juan Du, Richard F. Schlenk, M.D., Andrea Corbacioglu, Ph.D., Marianne Habdank, Claudia Scholl, M.D., Stefan Frohling, M.D., Lars Bullinger, M.D., Arnold Ganser, M.D., Hartmut Dohner, M.D., Konstanze Dohner, M.D.

Blood (2006) 108 (11): 2301.

https://doi.org/10.1182/blood.V108.11.2301.2301

Published: 2006

Journal Articles

RAS, KIT and FLT3 Gene Mutations in inv(16)/t(16;16)-Positive Acute Myeloid Leukemia (AML): Incidence and Relevance on Clinical Outcome.

Blood (2006) 108 (11): 2303.

https://doi.org/10.1182/blood.V108.11.2303.2303

Published: 2006

Journal Articles

Molecular Characterization of Distinct Hot Spot Regions on Chromosome 7q in Myeloid Leukemias.

Konstanze Dohner, MD, Marianne Habdank, Frank G. Rucker, M.D., Simone Miller, Stefan Frohling, M.D., Stephen W. Scherer, Ph.D., Lars Bullinger, M.D., Hartmut Dohner, M.D.

Blood (2006) 108 (11): 2349.

https://doi.org/10.1182/blood.V108.11.2349.2349

Published: 2006

Journal Articles

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

Konstanze Döhner, Richard F. Schlenk, Marianne Habdank, Claudia Scholl, Frank G. Rücker, Andrea Corbacioglu, Lars Bullinger, Stefan Fröhling, Hartmut Döhner, for the AML Study Group (AMLSG)

Blood (2005) 106 (12): 3740–3746.

https://doi.org/10.1182/blood-2005-05-2164

Published: 2005

NARROW

Clinical Relevance of Alternatively Spliced Isoform AML1-ETO9a in Adult Patients with t(8;21)(q22;q22.1) Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG)

CDK4/6 Inhibitor Palbociclib for Treatment of KMT2A -Rearranged Acute Myeloid Leukemia: Interim Analysis of the AMLSG 23-14 Trial

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome,

ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG

TET2 Mutations In Acute Myeloid Leukemia (AML): Results on 783 Patients Treated within the AML HD98A Study of the AML Study Group (AMLSG)

Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG).

Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG)

The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.

CEBPA Germline Mutation Screening in Cytogenetically Normal Acute Myeloid Leukemia with Somatically Acquired CEBPA Mutations.

Clinical Impact of WT1 Mutations in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG).

Detection of RAS, KIT and FLT3 Gene Mutations in t(8;21)-Positive Acute Myeloid Leukemia (AML): Evaluation of the Clinical Relevance.

RAS, KIT and FLT3 Gene Mutations in inv(16)/t(16;16)-Positive Acute Myeloid Leukemia (AML): Incidence and Relevance on Clinical Outcome.

Molecular Characterization of Distinct Hot Spot Regions on Chromosome 7q in Myeloid Leukemias.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only